Brief: Galapagos And Adaptimmune Sign Clinical Collaboration Agreement With An Option To Exclusively License Adaptimmune’s Uza-Cel In Head & Neck Cancer And Potential Future Solid Tumor Indications

Adaptimmune Therapeutics

30/05/2024 22:24

May 30 (Reuters) - Adaptimmune Therapeutics PLC
 ADAP.O :
    * REG-GALAPAGOS AND ADAPTIMMUNE SIGN CLINICAL COLLABORATION
AGREEMENT WITH AN OPTION TO EXCLUSIVELY LICENSE ADAPTIMMUNE’S
TCR T-CELL THERAPY CANDIDATE, UZA-CEL, IN HEAD & NECK CANCER AND
POTENTIAL FUTURE SOLID TUMOR INDICATIONS
    * GALAPAGOS NV: ADAPTIMMUNE TO RECEIVE INITIAL PAYMENTS OF
$100
MILLION
    * GALAPAGOS NV: ADAPTIMMUNE TO RECEIVE ADDITIONAL
DEVELOPMENT AND
SALES MILESTONE PAYMENTS OF UP TO A MAXIMUM OF $465 MILLION
    * GALAPAGOS NV: GALAPAGOS HAS BEEN GRANTED AN OPTION TO
EXCLUSIVELY LICENSE UZA-CEL FOR GLOBAL DEVELOPMENT AND
COMMERCIALIZATION IN HEAD & NECK CANCER
    * GALAPAGOS NV-GRANTED OPTION TO EXCLUSIVELY LICENSE UZA-CEL
FOR
GLOBAL DEVELOPMENT,COMMERCIALIZATION IN POTENTIAL FUTURE SOLID
TUMOR CANCER INDICATIONS

Source text for Eikon:  ID:nGNE82GRm0 
Further company coverage:  ADAP.O 

 ((Reutersbriefs@thomsonreuters.com;))